Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis

被引：3
|
作者：
Sekeres, M. [1 ]
Swern, A. [2 ]
Fenaux, P. [3 ]
Greenberg, P. [4 ]
Sanz, G. [5 ]
Bennett, J. [6 ]
Dreyfus, F. [7 ]
Cazzola, M. [8 ,9 ]
List, A. [10 ]
Garcia-Manero, G. [11 ]
Li, J. Shiansong [2 ]
Sugrue, M. [12 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH 44106 USA
[2] Celgene Corp, Biostat, Summit, NJ USA
[3] Avicenne Hosp, Dept Clin Hematol, Bobigny, France
[4] Stanford Univ, Div Hematol, Stanford, CA 94305 USA
[5] Hosp Univ & Politecn La Fe Valencia, Dept Hematol, Valencia, Spain
[6] Univ Rochester, Div Hematopathol & Hematol Oncol, Med Ctr, Rochester, NY 14627 USA
[7] Univ Paris, Hop Cochin, Dept Hematol, F-75252 Paris, France
[8] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[9] Univ Pavia, I-27100 Pavia, Italy
[10] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[12] Celgene Corp, Med Affairs, Summit, NJ USA
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70152-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-104
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [1] Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004
    Giagounidis, Aristoteles
    List, Alan
    Hellstroem-Lindberg, Eva
    Sekeres, Mikkael A.
    Mufti, Ghulam J.
    Schlegelberger, Brigitte
    Morrill, John
    Wu, Chengqing
    Skikne, Barry S.
    Fenaux, Pierre
    Goehring, Gudrun
    BLOOD, 2013, 122 (21)
  • [2] IMPACT OF 5Q BREAKPOINTS ON CLINICAL OUTCOMES IN PATIENTS WITH IPSS LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ISOLATED DEL(5Q) TREATED WITH LENALIDOMIDE IN THE MDS-004 STUDY
    Gohring, G.
    Giagounidis, A.
    List, A.
    Hellstrom-Lindberg, E.
    Sekeres, M.
    Mufti, G.
    Schlegelbergerl, B.
    Morrill, J.
    Wu, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2013, 98 : 80 - 80
  • [3] Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis
    Fenaux, Pierre
    Giagounidis, Aristoteles
    List, Alan F.
    Nimer, Stephen D.
    Hellstrom-Lindberg, Eva
    Powell, Bayard L.
    Yu, Xujie
    Skikne, Barry
    Shammo, Jamile M.
    del Canizo, Consuelo
    BLOOD, 2011, 118 (21) : 750 - 751
  • [4] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    M A Sekeres
    A S Swern
    P Fenaux
    P L Greenberg
    G F Sanz
    J M Bennett
    F Dreyfus
    A F List
    J S Li
    M M Sugrue
    Blood Cancer Journal, 2014, 4 : e242 - e242
  • [5] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    Sekeres, M. A.
    Swern, A. S.
    Fenaux, P.
    Greenberg, P. L.
    Sanz, G. F.
    Bennett, J. M.
    Dreyfus, F.
    List, A. F.
    Li, J. S.
    Sugrue, M. M.
    BLOOD CANCER JOURNAL, 2014, 4 : e242 - e242
  • [6] Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.
    Fenaux, P.
    Glagounidis, A.
    Selleslag, D. L.
    Beyne-Rauzy, O.
    Mittelman, M.
    Muus, P.
    Knight, R. D.
    Fu, T.
    Hellstrom-Lindberg, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)
    Schemenau, J.
    Lauseker, M.
    Hildebrandt, B.
    Fenaux, P.
    Pfeilstoecker, M.
    Valent, P.
    Platzbecker, U.
    Kuendgen, A.
    Bug, G.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S157 - S157
  • [8] The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
    Kaivers, J.
    Lauseker, M.
    Hildebrandt, B.
    Fenaux, P.
    Pfeilstoecker, M.
    Valent, P.
    Platzbecker, U.
    Latagliata, R.
    Oliva, E. N.
    Xicoy, B.
    Goetze, K.
    Ganster, C.
    Haase, D.
    Bug, G.
    Kuendgen, A.
    Gattermann, N.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2018, 72 : 27 - 33
  • [9] Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes
    Giagounidis, Aristoteles
    Raza, Azra
    List, Alan F.
    Fenaux, Pierre
    Benettaib, Bouchra
    Brown, Benton
    Zhong, Jim
    Brandenburg, Nancy
    Mufti, Ghulam J.
    BLOOD, 2011, 118 (21) : 742 - 743
  • [10] Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies
    Giagounidis, Aristoteles
    List, Alan F.
    Hellstroem-Lindberg, Eva
    Mufti, Ghulam J.
    Schlegelberger, Brigitte
    Morrill, John
    Wu, Chengqing
    Skikne, Barry S.
    Fenaux, Pierre
    Goehring, Gudrun
    BLOOD, 2015, 126 (23)
12345